Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
Morishita
Shigeru
S
Department of Psychiatry, Kawasaki Medical School, 577 Matsushima, Kurashiki-city, 701-0192 Okayama, Japan. morisita@med.kawasaki-m.ac.jp
Arita
Seizaburo
S
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D015331:Cohort Studies; D003521:Cyclopropanes / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D016666:Fluvoxamine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078764:Milnacipran; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use*; D010555:Personality Inventory / Q000706:statistics & numerical data; D011594:Psychometrics; D012189:Retrospective Studies; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012737:Sex Factors; D016896:Treatment Outcome
D018759:Adrenergic Uptake Inhibitors; D018687:Antidepressive Agents, Second-Generation; D003521:Cyclopropanes; D016666:Fluvoxamine; D000078764:Milnacipran; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors